Meet The
Genomadix Cube

The Genomadix Cube is a fast, accurate, and portable DNA analyzer. Get quality results outside of a lab.

Rapid Results

Traditional lab-based tests can take days to weeks for results. In contrast, the Genomadix Cube goes from sample to result in approximately an hour. Results are more accessible.


The Genomadix Cube was designed to be used as a decentralized testing option. This is especially helpful for remote communities and remote industries where access to a full lab may be difficult. 


The Genomadix Cube uses the gold standard of Polymerase Chain Reaction (PCR) to get accurate results the first time. The Genomadix Cube provides high quality results outside of a lab. 

The Genomadix Cube is For:

Health Care Professional

Remote Communities

ui vol.1

Medical Distributors

Government Bodies


Commercial Industries

How it works

  • Samples are collected and inserted into a single-use DNA test cartridge.
  • Inside the analyzer, the cartridge extracts the DNA/RNA and makes millions of copies based on chemistry called Polymerase Chain Reaction (PCR).
  • An optical system detects the increased fluorescence and algorithms automatically generate a test result.

High Quality Results

Outside The Lab

While more are in development, our current products include tests for COVID-19, Legionella bacteria, and CYP2C19 genotyping. These tests are run using their own unique software on the Genomadix Cube.


Rapid identification of the COVID-19 virus.


Rapid genotyping for antiplatelet therapy. 



Rapid identification of Legionella bacteria in water systems.

Clinical Studies Leveraging the Genomadix Cube

New England Journal of Medicine: A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI

  • This randomized, prospective trial of 2,488 patients undergoing primary PCI with stent implantation assessed the use of a genotype-guided approach to oral P2Y12 inhibitor selection
    Read More
  • This study showed that a genotype-guided approach to therapy was noninferior to standard treatment with ticagrelor or prasugrel with respect to thrombotic events, and resulted in a lower incidence of bleeding
  • Considering that ticagrelor/prasugrel cost 10-20X more than generic clopidogrel, CYP2C19 genotyping can significantly lower healthcare costs
    Read Less

The Lancet: Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

  • Rapid genetic testing after PCI can be effectively done at the bedside to identify CYP2C19*2 LOF allele carriers
    Read More
  • This prospective, randomized 200-patient study reported that tailored, genotype-guided treatment of CYP2C19*2 carriers can reduce high on-treatment platelet reactivity, which is commonly associated with increased risk for major adverse cardiovascular events
  • This study is the first reported use of an FDA-cleared, rapid CYP2C19 genetic test, and offers a novel solution to overcome limitations in pharmacogenomics
    Read Less

Journal of the American Medical Association: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention

  • Genotype-guided therapy resulted in 34% fewer adverse events after 12 months such as death, stroke, second heart attack, and stent thrombosis.
    Read More
  • Genotype-guided therapy resulted in 79% fewer adverse events in the first 3 months. According to principal investigator Dr. Naveen Pereira: “This finding suggests that the lion’s share of the benefit of genetically guided therapy may occur during this high-risk period.”
    Read Less

Is Our Technology Right for You?